238 related articles for article (PubMed ID: 19066328)
1. Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome.
Robinson SP; Sureda A; Canals C; Russell N; Caballero D; Bacigalupo A; Iriondo A; Cook G; Pettitt A; Socie G; Bonifazi F; Bosi A; Michallet M; Liakopoulou E; Maertens J; Passweg J; Clarke F; Martino R; Schmitz N;
Haematologica; 2009 Feb; 94(2):230-8. PubMed ID: 19066328
[TBL] [Abstract][Full Text] [Related]
2. Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Español de Linfomas/Trasplante de Médula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
Sureda A; Canals C; Arranz R; Caballero D; Ribera JM; Brune M; Passweg J; Martino R; Valcárcel D; Besalduch J; Duarte R; León A; Pascual MJ; García-Noblejas A; López Corral L; Xicoy B; Sierra J; Schmitz N
Haematologica; 2012 Feb; 97(2):310-7. PubMed ID: 21993674
[TBL] [Abstract][Full Text] [Related]
3. Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation.
Peggs KS; Hunter A; Chopra R; Parker A; Mahendra P; Milligan D; Craddock C; Pettengell R; Dogan A; Thomson KJ; Morris EC; Hale G; Waldmann H; Goldstone AH; Linch DC; Mackinnon S
Lancet; 2005 Jun 4-10; 365(9475):1934-41. PubMed ID: 15936420
[TBL] [Abstract][Full Text] [Related]
4. Brentuximab vedotin prior to allogeneic stem cell transplantation increases survival in chemorefractory Hodgkin's lymphoma patients.
Gaudio F; Mazza P; Mele A; Palazzo G; Carella AM; Delia M; Pisapia G; Pastore D; Cascavilla N; Pavone V; Specchia G
Ann Hematol; 2019 Jun; 98(6):1449-1455. PubMed ID: 30868307
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Hodgkin Lymphomas: A Retrospective Multicenter Experience by the Rete Ematologica Pugliese (REP).
Gaudio F; Mazza P; Carella AM; Mele A; Palazzo G; Pisapia G; Carluccio P; Pastore D; Cascavilla N; Specchia G; Pavone V
Clin Lymphoma Myeloma Leuk; 2019 Jan; 19(1):35-40. PubMed ID: 30293754
[TBL] [Abstract][Full Text] [Related]
6. Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes.
Peggs KS; Sureda A; Qian W; Caballero D; Hunter A; Urbano-Ispizua A; Cavet J; Ribera JM; Parker A; Canales M; Mahendra P; Garcia-Conde J; Milligan D; Sanz G; Thomson K; Arranz R; Goldstone AH; Alvarez I; Linch DC; Sierra J; Mackinnon S;
Br J Haematol; 2007 Oct; 139(1):70-80. PubMed ID: 17854309
[TBL] [Abstract][Full Text] [Related]
7. Long-term outcome of patients receiving haematopoietic allogeneic stem cell transplantation as first transplant for high-risk Hodgkin lymphoma: a retrospective analysis from the Lymphoma Working Party-EBMT.
Gutiérrez-García G; Martínez C; Boumendil A; Finel H; Malladi R; Afanasyev B; Tsoulkani A; Wilson KMO; Bloor A; Nikoloudis M; Richardson D; López-Corral L; Castagna L; Cornelissen J; Giltat A; Collin M; Fanin R; Bonifazi F; Robinson S; Montoto S; Peggs KS; Sureda A
Br J Haematol; 2022 Feb; 196(4):1018-1030. PubMed ID: 34750806
[TBL] [Abstract][Full Text] [Related]
8. Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-hodgkin lymphomas.
Hamadani M; Benson DM; Hofmeister CC; Elder P; Blum W; Porcu P; Garzon R; Blum KA; Lin TS; Marcucci G; Devine SM
Biol Blood Marrow Transplant; 2009 May; 15(5):547-53. PubMed ID: 19361746
[TBL] [Abstract][Full Text] [Related]
9. Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a spanish prospective cooperative protocol.
Alvarez I; Sureda A; Caballero MD; Urbano-Ispizua A; Ribera JM; Canales M; García-Conde J; Sanz G; Arranz R; Bernal MT; de la Serna J; Díez JL; Moraleda JM; Rubió-Félix D; Xicoy B; Martínez C; Mateos MV; Sierra J
Biol Blood Marrow Transplant; 2006 Feb; 12(2):172-83. PubMed ID: 16443515
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic haematopoietic stem-cell transplantation with reduced intensity conditioning for advanced stage Hodgkin's lymphoma in Sweden: high incidence of post transplant lymphoproliferative disorder.
Johansson JE; Remberger M; Lazarevic VLj; Hallböök H; Wahlin A; Kimby E; Juliusson G; Omar H; Hägglund H
Bone Marrow Transplant; 2011 Jun; 46(6):870-5. PubMed ID: 20956959
[TBL] [Abstract][Full Text] [Related]
11. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
Sureda A; Robinson S; Canals C; Carella AM; Boogaerts MA; Caballero D; Hunter AE; Kanz L; Slavin S; Cornelissen JJ; Gramatzki M; Niederwieser D; Russell NH; Schmitz N
J Clin Oncol; 2008 Jan; 26(3):455-62. PubMed ID: 18086796
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic transplantation for Hodgkin's lymphoma.
Corradini P; Sarina B; Farina L
Br J Haematol; 2011 Feb; 152(3):261-72. PubMed ID: 21155760
[TBL] [Abstract][Full Text] [Related]
13. Impact of disease status and stem cell source on the results of reduced intensity conditioning transplant for Hodgkin's lymphoma: a retrospective study from the French Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC).
Marcais A; Porcher R; Robin M; Mohty M; Michalet M; Blaise D; Tabrizi R; Clement L; Ceballos P; Daguindau E; Bilger K; Dhedin N; Lapusan S; Bay JO; Pautas C; Garban F; Ifrah N; Guillerm G; Contentin N; Bourhis JH; Yakoub Agha I; Bernard M; Cornillon J; Milpied N
Haematologica; 2013 Sep; 98(9):1467-75. PubMed ID: 23539540
[TBL] [Abstract][Full Text] [Related]
14. Allogeneic cell therapy for patients who relapse after autologous stem cell transplantation.
Porter DL; Luger SM; Duffy KM; Stadtmauer EA; Laport G; Schuster SJ; Orloff G; Tsai D; McDaid K; Kathakali A; Leonard DG; Antin JH
Biol Blood Marrow Transplant; 2001; 7(4):230-8. PubMed ID: 11349810
[TBL] [Abstract][Full Text] [Related]
15. Unrelated donor reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma.
Devetten MP; Hari PN; Carreras J; Logan BR; van Besien K; Bredeson CN; Freytes CO; Gale RP; Gibson J; Giralt SA; Goldstein SC; Gupta V; Marks DI; Maziarz RT; Vose JM; Lazarus HM; Anderlini P
Biol Blood Marrow Transplant; 2009 Jan; 15(1):109-17. PubMed ID: 19135949
[TBL] [Abstract][Full Text] [Related]
16. Outcome of lower-intensity allogeneic transplantation in non-Hodgkin lymphoma after autologous transplantation failure.
Freytes CO; Zhang MJ; Carreras J; Burns LJ; Gale RP; Isola L; Perales MA; Seftel M; Vose JM; Miller AM; Gibson J; Gross TG; Rowlings PA; Inwards DJ; Pavlovsky S; Martino R; Marks DI; Hale GA; Smith SM; Schouten HC; Slavin S; Klumpp TR; Lazarus HM; van Besien K; Hari PN
Biol Blood Marrow Transplant; 2012 Aug; 18(8):1255-64. PubMed ID: 22198543
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
[TBL] [Abstract][Full Text] [Related]
18. Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Nagler A; Labopin M; Houhou M; Aljurf M; Mousavi A; Hamladji RM; Al Zahrani M; Bondarenko S; Arat M; Angelucci E; Koc Y; Gülbas Z; Sica S; Bourhis JH; Canaani J; Brissot E; Giebel S; Mohty M
J Hematol Oncol; 2021 Apr; 14(1):53. PubMed ID: 33794963
[TBL] [Abstract][Full Text] [Related]
19. Autotransplants for Hodgkin's disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR).
Lazarus HM; Loberiza FR; Zhang MJ; Armitage JO; Ballen KK; Bashey A; Bolwell BJ; Burns LJ; Freytes CO; Gale RP; Gibson J; Herzig RH; LeMaistre CF; Marks D; Mason J; Miller AM; Milone GA; Pavlovsky S; Reece DE; Rizzo JD; van Besien K; Vose JM; Horowitz MM
Bone Marrow Transplant; 2001 Feb; 27(4):387-96. PubMed ID: 11313668
[TBL] [Abstract][Full Text] [Related]
20. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]